AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3531862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin
Number of subjects: 115
Study 3531862 — intervention group
Group type: COMPARATOR
Intervention: Intermittent subcutaneous heparin
Number of subjects: 115
Study 30280654 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator plus guideline-directed therapy
Number of subjects: 2302
Study 30280654 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed therapy only (control group)
Number of subjects: 2302
Study 26663817 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (25 mg three times a day for 12 weeks)
Number of subjects: 72
Study 26663817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25591511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40
Study 25591511 — intervention group
Group type: COMPARATOR
Intervention: Traditional medicinal treatment
Number of subjects: 40
Study 22460067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarush initiation (3 visits over 2 weeks)
Number of subjects: 213
Study 22460067 — intervention group
Group type: COMPARATOR
Intervention: Semirush initiation (10 visits over 9 weeks)
Number of subjects: 213
Study 22460067 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of 50 μg
Number of subjects: 213
Study 22460067 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose of 100 μg
Number of subjects: 213
Study 20091327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW)
Number of subjects: 135
Study 20091327 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HW)
Number of subjects: 135
Study 20091327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW) and Heavyweight mesh (HW)
Number of subjects: 135
Study 18174779 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker-based program
Number of subjects: 0
Study 18174779 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker-based treatment regimen
Number of subjects: 0
Study 18174779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-drug therapy (therapy with > or =2 medications)
Number of subjects: 0
Study 18174779 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 0
Study 15954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated sonic scaler insert (tSS)
Number of subjects: 82
Study 15954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sonic scaler (SS)
Number of subjects: 82
Study 15954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracey curette
Number of subjects: 82
Study 15954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic scaler insert (US)
Number of subjects: 82
Study 15954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating Periotor insert (PT)
Number of subjects: 82
Study 15954250 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 82
Study 12872679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (daily treatment for 3 years)
Number of subjects: 20
Study 12872679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily treatment for 3 years)
Number of subjects: 20
Study 10567781 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once daily)
Number of subjects: 13
Study 10567781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7587910 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid ethyl (EPA-E) 900 mg/day
Number of subjects: 0
Study 2082783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duxil
Number of subjects: 204
Study 2082783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 120541 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (1 g/kg in orange juice)
Number of subjects: 10
Study 120541 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (1 g/kg in orange juice) plus CBD (200 mg capsule)
Number of subjects: 10
Study 120541 — intervention group
Group type: COMPARATOR
Intervention: CBD (200 mg capsule)
Number of subjects: 10
Study 120541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose capsule and orange juice)
Number of subjects: 10
Study 31184996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocellular foam dressing
Number of subjects: 80
Study 31184996 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid plate dressing
Number of subjects: 80
Study 29455384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Moms Training (MMT)
Number of subjects: 46
Study 29455384 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Brain Training (EBT)
Number of subjects: 46
Study 26872000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72
Study 26872000 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 72
Study 25317090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 500 mg
Number of subjects: 377
Study 25317090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 250 mg
Number of subjects: 377
Study 25317090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 22679719 — intervention group
Group type: EXPERIMENTAL
Intervention: Shencao Tongmai Granule (STG) plus Western medicine (WM) treatment
Number of subjects: 280
Study 22679719 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Western medicine (WM) treatment
Number of subjects: 280
Study 22679719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 280
Study 20599196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained uterine massage
Number of subjects: 1964
Study 20599196 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 1964
Study 20599196 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin plus sustained uterine massage
Number of subjects: 1964
Study 17670757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorin Freedom stentless valve
Number of subjects: 60
Study 17670757 — intervention group
Group type: COMPARATOR
Intervention: Sorin More stented valve
Number of subjects: 60
Study 15918119 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 12076231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only
Number of subjects: 82
Study 12076231 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program that included exercise
Number of subjects: 82
Study 12076231 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 82
Study 9809893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (direct thrombin inhibitor)
Number of subjects: 17000
Study 9809893 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 17000
Study 7714265 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Amplitude Modulation (RAM)
Number of subjects: 0
Study 7714265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal Amplitude Modulation (SAM)
Number of subjects: 0
Study 2490827 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for hypertension (including thiazide-like diuretic agents)
Number of subjects: 43000
Study 2490827 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for hypertension
Number of subjects: 43000
Study 946209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine produced in human diploid cell culture (WI-38)
Number of subjects: 31
Study 946209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine produced in hamster kidney-cell culture
Number of subjects: 31
Study 7377574 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, 8 mg
Number of subjects: 21
Study 7377574 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, 4 mg
Number of subjects: 21
Study 7377574 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 21
Study 31882012 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care Plus LEF-SCP
Number of subjects: 75
Study 31882012 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care Plus LEF-SCP Plus Follow-Up
Number of subjects: 75
Study 31882012 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 75
Study 30210819 — intervention group
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Number of subjects: 60
Study 30210819 — intervention group
Group type: COMPARATOR
Intervention: ID93 alone
Number of subjects: 60
Study 26733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I) followed by Positive Airway Pressure (PAP)
Number of subjects: 0
Study 26733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I) and Positive Airway Pressure (PAP) administered concurrently
Number of subjects: 0
Study 26733360 — intervention group
Group type: COMPARATOR
Intervention: Positive Airway Pressure (PAP) alone
Number of subjects: 0
Study 24742739 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg/day) plus trastuzumab (2 mg/kg) and vinorelbine (25 mg/m(2))
Number of subjects: 569
Study 24742739 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and vinorelbine
Number of subjects: 569
Study 22431673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 808
Study 22431673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 808
Study 22431673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 808
Study 22431673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 20232280 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin immune Fab (DIF)
Number of subjects: 51
Study 20232280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17924890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 45
Study 17924890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% combined with general anaesthesia
Number of subjects: 45
Study 17924890 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 45
Study 16305009 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips (Crest Whitestrips Premium)
Number of subjects: 40
Study 16305009 — intervention group
Group type: COMPARATOR
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 40
Study 11909936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-promoting interaction
Number of subjects: 120
Study 11909936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-reducing interaction
Number of subjects: 120
Study 11909936 — intervention group
Group type: COMPARATOR
Intervention: No training control group
Number of subjects: 120
Study 9568921 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester alcohol use
Number of subjects: 74
Study 9568921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use during each of the three trimesters
Number of subjects: 74
Study 9568921 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester marijuana use
Number of subjects: 74
Study 9568921 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester other illicit drug use
Number of subjects: 74
Study 8549258 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession educational program about the care of residents with diabetes
Number of subjects: 0
Study 8549258 — intervention group
Group type: COMPARATOR
Intervention: Control group (nursing staffs from two other similar facilities who did not participate in the educational program)
Number of subjects: 0
Study 2197635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 1 g xantinolnicotinate (Complamin)
Number of subjects: 150
Study 2197635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 320808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of 2% plain prilocaine
Number of subjects: 10
Study 320808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of 2% plain mepivacaine
Number of subjects: 10
Study 320808 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 29696736 — intervention group
Group type: EXPERIMENTAL
Intervention: BECM group (bismuth added)
Number of subjects: 66
Study 29696736 — intervention group
Group type: COMPARATOR
Intervention: ECM group (no bismuth)
Number of subjects: 66
Study 27905522 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month resistance exercise training with dietary intervention
Number of subjects: 101
Study 27905522 — intervention group
Group type: COMPARATOR
Intervention: 6-month resistance exercise training without dietary intervention
Number of subjects: 101
Study 24694553 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigation
Number of subjects: 130
Study 24694553 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D navigation
Number of subjects: 130
Study 24694553 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 130
Study 22634969 — intervention group
Group type: EXPERIMENTAL
Intervention: SHORT warm-up (30 minutes lower intensity)
Number of subjects: 14
Study 22634969 — intervention group
Group type: COMPARATOR
Intervention: LONG warm-up (traditional warm-up)
Number of subjects: 14
Study 22634969 — intervention group
Group type: COMPARATOR
Intervention: LONG warm-up
Number of subjects: 14
Study 20458108 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits to family physicians
Number of subjects: 4999
Study 20458108 — intervention group
Group type: COMPARATOR
Intervention: Visits to pediatricians
Number of subjects: 4999
Study 18312708 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 239
Study 18312708 — intervention group
Group type: COMPARATOR
Intervention: Scissors
Number of subjects: 239
Study 15717255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 468
Study 15717255 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 468
Study 12843161 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg mixed esters)
Number of subjects: 51
Study 12843161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg)
Number of subjects: 51
Study 12843161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10983343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (parenteral administration)
Number of subjects: 90
Study 10983343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (intra-arterial or local use)
Number of subjects: 90
Study 8738539 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-treated catheters (Spi-Argent n=14; Spi-Silicone n=16)
Number of subjects: 56
Study 8738539 — intervention group
Group type: COMPARATOR
Intervention: Untreated catheters
Number of subjects: 56
Study 1583340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (1 mg clearing dose followed by either one or two 200 micrograms/kg doses)
Number of subjects: 30
Study 1583340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (12 daily 6 mg/kg doses)
Number of subjects: 30
Study 1583340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 1583340 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison of IgG levels)
Number of subjects: 30
Study 3905392 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (7.5 ng X kg‐1 X min‐1)
Number of subjects: 7
Study 3905392 — intervention group
Group type: COMPARATOR
Intervention: Saline solution infusion (control)
Number of subjects: 7
Study 3905392 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 7
Study 30597550 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated treatment
Number of subjects: 42
Study 29694316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) + Treatment as Usual (TAU)
Number of subjects: 101
Study 29694316 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 101
Study 26444907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% and betamethasone dipropionate 0.064% aerosol foam
Number of subjects: 376
Study 26444907 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment
Number of subjects: 376
Study 26444907 — intervention group
Group type: COMPARATOR
Intervention: Aerosol foam vehicle
Number of subjects: 376
Study 26444907 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 376
Study 25045768 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1072 mgF/kg)
Number of subjects: 11
Study 25045768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (513 mgF/kg)
Number of subjects: 11
Study 25045768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fluoride-free)
Number of subjects: 11
Study 22488499 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle exercises (PG-PFME)
Number of subjects: 66
Study 22488499 — intervention group
Group type: COMPARATOR
Intervention: Folder-based pelvic floor muscle exercises (F-PFME)
Number of subjects: 66
Study 22488499 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative detrusor overactivity (DOA)
Number of subjects: 66
Study 22488499 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urodynamic parameters
Number of subjects: 66
Study 20130406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis (EFA)
Number of subjects: 778
Study 20130406 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA)
Number of subjects: 778
Study 18499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intra-arterial vitamin C administration (24 mg min(‐1))
Number of subjects: 33
Study 18499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral vitamin C supplementation (500 mg day(‐1))
Number of subjects: 33
Study 15949096 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 per cent lignocaine
Number of subjects: 58
Study 15949096 — intervention group
Group type: COMPARATOR
Intervention: 0.9 per cent saline
Number of subjects: 58
Study 12915645 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic association of 40/30 micro g ethinyl estradiol (EE) and 25/125 micro g desogestrel (DSG)
Number of subjects: 20
Study 12915645 — intervention group
Group type: COMPARATOR
Intervention: Monophasic association of 35 micro g EE and 2 mg cyproterone acetate (CPA)
Number of subjects: 20
Study 14677619 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD 60 microg/EE 15 microg for 24 days
Number of subjects: 27
Study 8906382 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable contact lenses
Number of subjects: 338
Study 8906382 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily wear contact lenses
Number of subjects: 338
Study 8906382 — intervention group
Group type: COMPARATOR
Intervention: Frequent replacement (1/3 months) contact lenses
Number of subjects: 338
Study 8906382 — intervention group
Group type: COMPARATOR
Intervention: Frequent replacement (2-weeks) contact lenses
Number of subjects: 338
Study 2052854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 58
Study 2052854 — intervention group
Group type: COMPARATOR
Intervention: DEC 3 mg/kg
Number of subjects: 58
Study 2052854 — intervention group
Group type: COMPARATOR
Intervention: DEC 6 mg/kg
Number of subjects: 58
Study 6191906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day ISO for 7 days
Number of subjects: 60
Study 6191906 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day ISO for 7 days
Number of subjects: 60
Study 6191906 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 7 days
Number of subjects: 60
Study 31977099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics training utilizing photography (N=15)
Number of subjects: 30
Study 31977099 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=15)
Number of subjects: 30
Study 30777112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) for a 3-day course
Number of subjects: 0
Study 30777112 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and co-design of information messages
Number of subjects: 0
Study 30329175 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Immunoglobulin (IVIG)
Number of subjects: 40
Study 30329175 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange (TPE)
Number of subjects: 40
Study 27693836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention care bundle
Number of subjects: 1600
Study 27693836 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1600
Study 24485800 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) combined with cognitive training
Number of subjects: 33
Study 24485800 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with cognitive training
Number of subjects: 33
Study 22409711 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB)
Number of subjects: 40
Study 22409711 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 (moderate dose)
Number of subjects: 40
Study 22409711 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 (low dose)
Number of subjects: 40
Study 22409711 — intervention group
Group type: COMPARATOR
Intervention: UVA1 (both doses)
Number of subjects: 40
Study 20884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent with bioabsorbable coating (SES)
Number of subjects: 95
Study 20884414 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 95
Study 17405806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 19
Study 17405806 — intervention group
Group type: COMPARATOR
Intervention: Neurological Rehabilitation (NR)
Number of subjects: 19
Study 16619801 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler imaging in preterm infants
Number of subjects: 55